Finance entity
Every one of those 2 sits in a single category, markets. AstraZeneca is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 9, the average consequence score sits above the same-window beat average of 5.8.
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, markets. AstraZeneca is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 9, the average consequence score sits above the same-window beat average of 5.8. Source depth averages 3 original sources per story, versus 2.3 across the same-window beat baseline. Pascal Soriot appears in 2 tracked Finance stories published from August 2, 2026 through August 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 44 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pascal Soriot. Shared-story counts are live from our verified record — not editorial picks.
AstraZeneca shares plummeted in London trading after reports of merger talks with Bristol Myers Squibb, as the market priced in execution risk, regulatory peril, and potential overpayment for a deal that would create a £300bn giant.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
Pascal Soriot is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
